Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

Hyams, Jeffrey S; Dubinsky, Marla C; Baldassano, Robert N; Colletti, Richard B; Cucchiara, Salvatore; Escher, Johanna; Faubion, William; Fell, John; Gold, Benjamin D; Griffiths, Anne; Koletzko, Sibylle; Kugathasan, Subra; Markowitz, James; Ruemmele, Frank M; Veereman, Gigi; Winter, Harland; Masel, Nicholas; Shin, Chu Ri; Tang, Kezhen L; Thayu, Meena

doi:10.1053/j.gastro.2017.02.004

Citations

Citation copied

Hyams, J. S., Dubinsky, M. C., Baldassano, R. N., Colletti, R. B., Cucchiara, S., Escher, J., Faubion, W., Fell, J., Gold, B. D., Griffiths, A., Koletzko, S., Kugathasan, S., Markowitz, J., Ruemmele, F. M., Veereman, G., Winter, H., Masel, N., Shin, C. R., Tang, K. L., & Thayu, M. (2017). Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology, 152(8), 1901-1914.e3. https://doi.org/10.1053/j.gastro.2017.02.004

Abstract

BACKGROUND AND AIMS: Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis (HLH). We compared unadjusted incidence rates of malignancy and HLH in pediatric patients with IBD exposed to infliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (SIRs). METHODS: We collected and analyzed data from 5766 participants in a prospective study of